915230-14-7

Usage

Uses

Used in Organic Synthesis:
4,4-Difluoro-L-proline Methyl ester trifluoroacetate is used as a building block in organic synthesis for its unique chemical structure and reactivity. It allows for the creation of a variety of complex organic molecules, contributing to the development of new compounds with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4,4-Difluoro-L-proline Methyl ester trifluoroacetate is used as a key intermediate in the synthesis of pharmaceuticals. Its modified structure allows for the development of new drugs with improved properties, such as increased potency, selectivity, and bioavailability.
Used in the Synthesis of Biologically Active Compounds:
4,4-Difluoro-L-proline Methyl ester trifluoroacetate is employed as a starting material in the synthesis of biologically active compounds. Its unique properties enable the creation of molecules with potential therapeutic effects, contributing to the discovery of new treatments for various diseases and conditions.
Used in Pharmaceutical Industry:
4,4-Difluoro-L-proline Methyl ester trifluoroacetate is used as a crucial component in the development of new pharmaceuticals. Its incorporation into drug molecules can lead to enhanced efficacy, reduced side effects, and improved pharmacokinetic properties, ultimately benefiting patients and advancing medical treatments.

Upstream product

• 76-05-1 trifluoroacetic acid 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 256487-77-1 (R)-4-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 647857-74-7 methyl (R)-1-tert-butoxycarbonyl-4,4-difluoropyrrolidine-2-carboxylate 

Downstream Products

• 915230-15-8 (S)-4,4-difluoro-N-tosyl-pyrrolidine-2-carboxylic acid methyl ester 
• 475561-89-8 4-fluoro-1H-pyrrole-2-carboxylic acid methyl ester 
• 475561-90-1 4-fluoro-pyrrole-2-carboxylic acid 

Relevant academic research and scientific papers

Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors

Targeting the capsid protein of hepatitis B virus (HBV) and thus interrupting normal capsid formation have been an attractive approach to block the replication of HBV viruses. We carried out multidimensional structural optimizations based on the heteroaryldihydropyrimidine (HAP) analogue Bay41-4109 (1) and identified a novel series of HBV capsid inhibitors that demonstrated promising cellular selectivity indexes, metabolic stabilities, and in vitro safety profiles. Herein we disclose the design, synthesis, structureactivity relationship (SAR), cocrystal structure in complex with HBV capsid proteins and in vivo pharmacological study of the 4-methyl HAP analogues. In particular, the (2S,4S)-4,4-difluoroproline substituted analogue 34a demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load reduction in a hydrodynamic injected (HDI) HBV mouse model.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

PHENYL-3-{ (3- (1H- PYRROL- 2 -YL) - [1 , 2 , 4] 0XADIAZ0L-5-YL] PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluKi is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkeiiyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=0)-0-, -0-C(=0)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-0-, -0-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.